MedTest Dx FDA-approved quantitative test for G6PD
May 2020—MedTest Dx announced the availability of its Pointe Scientific–branded assay for the highly sensitive quantification of G6PD in whole blood.
Webinars and Sponsored Roundtables — Register Now
Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Biocare launches seven IVD antibodies
May 2020—Biocare Medical launched seven novel IVD IHC antibody markers for clinical diagnostics and research applications. This launch focuses on several immuno-oncology markers, critical in aiding early-stage cancer drug developments and patient treatment.
COVID-19 proficiency testing
May 2020—The CAP has released a new proficiency testing program for the detection of SARS-CoV-2 by nucleic acid amplification testing.
EKF launches β-ketone, glucose POC analyzer
May 2020—EKF Diagnostics has launched in the United States its Stat-Site WB dual-use whole blood β-ketone and glucose meter for professional use in the management of diabetes. The CLIA-waived handheld analyzer quantitatively measures β-ketone (beta-hydroxybutyrate) from fresh capillary and venous whole blood in 10 seconds and delivers quantitative measurements in five seconds for glucose in fresh capillary, venous, and neonatal whole blood. The system has a measurement range of 0.1–8.0 mmol/L for β-ketone and 0.5–33.3 mmol/L for blood glucose. Its hematocrit range is 10–70 percent for β-ketone and 20–70 percent for blood glucose.
BD Kiestra ReadA device listed with the FDA
May 2020—BD announced that its BD Kiestra ReadA is device listed with the FDA. The BD Kiestra ReadA incubation and imaging system, which is available as a standalone instrument, aims to help improve operational efficiency in clinical microbiology laboratories by automating routine plate management tasks and delivering accuracy through standardized digital image acquisition. BD, 201-847-6800
MilliporeSigma to manufacture Elypta liquid biopsy kits
May 2020—MilliporeSigma has been selected by Swedish molecular diagnostics company Elypta as the contract manufacturer for Elypta’s clinical diagnostic liquid biopsy kits. The kits analyze metabolites deregulated in several cancer types and will initially be made available for research use only. They are intended for mass spectrometry systems and will allow qualified researchers to measure the full spectrum of human glycosaminoglycans in body fluid samples.
Viracor Eurofins gets EUA for SARS-CoV-2 LDT
May 2020—Viracor Eurofins was granted FDA emergency use authorization for the Viracor SARS-CoV-2 assay, a real-time polymerase chain reaction test intended for the qualitative detection of SARS-CoV-2 viral RNA in nasopharyngeal swab, nasal swab, nasopharyngeal wash, nasal wash, oropharyngeal swab, and bronchoalveolar lavage from individuals suspected of having COVID-19.
Ortho launches second COVID-19 antibody test
May 2020—Ortho Clinical Diagnostics announced the FDA granted emergency use authorization to its second COVID-19 antibody test—the Vitros Immunodiagnostic Products Anti-SARS-CoV-2 IgG Test. The test demonstrated 100 percent specificity and runs on Ortho’s high-throughput, fully automated analyzers including its Vitros XT 7600 integrated system, Vitros 3600 immunodiagnostic system, Vitros 5600 integrated system, and it will soon be available on Vitros ECi/ECiQ immunodiagnostic systems.
Thermo Fisher, Janssen to co-develop cancer CDx
May 2020—Thermo Fisher Scientific has signed an agreement with Janssen Biotech to co-develop a companion diagnostic in oncology. The diagnostic will support clinical trial enrollment worldwide.
Horizon CHOsource platform
May 2020—Horizon Discovery Group announced its cGMP-compliant CHOsource platform has played a key role in generating a stable cell line for the development of an immunotherapy for autoimmune diseases. Horizon’s Chinese hamster ovary cells delivered high yields of monoclonal antibody for LAG-3 immunotherapy, the company reported in a press statement, enabling Immutep and Batavia Biosciences to reach a milestone in the preclinical development of the compound.